文献速递瓣膜病与结构性心脏病

球囊扩张式TAVR的病例量与结局:来自TVT登记的研究

Case Volume and Outcomes After TAVR With Balloon-Expandable Prostheses: Insights From TVT Registry.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

基于TVT登记2011年11月至2017年1月61,949例球囊扩张式TAVR植入数据,分析病例量与结局关系。结果显示全体球囊扩张瓣膜类型存在初始学习曲线,约在201例终止,之后未见病例量与结局关系;仅Sapien 3分析未见学习曲线或病例量结局关系。

要点

  • 全体球囊扩张式TAVR病例经验约200例后学习曲线终止,之后病例量与结局关系不再明显。
  • 仅Sapien 3分析中未观察到学习曲线或病例量与结局关系。
  • 当前代球囊扩张式TAVR中心即使早期病例经验也应预期获得一致优异结局。

核心结论

  • 球囊扩张式TAVR病例经验约200例后学习曲线终止,之后病例量与结局关系不再明显。
  • 仅Sapien 3分析中未观察到学习曲线或可证明的病例量与结局关系。

研究设计与样本

  • 回顾性分析TVT登记2011年11月至2017年1月球囊扩张式TAVR植入数据,共61,949例。
  • 主要结局为30天全因死亡、卒中和主要血管并发症。
  • 按病例序列号排序,采用网格搜索分析确定学习曲线终止点,之后评估每月病例量的病例量与结局关系。
  • 分析分别针对所有球囊扩张瓣膜类型、仅Sapien 3、以及Sapien 3在球囊扩张瓣膜初治中心。

主要发现

  • 全体球囊扩张瓣膜类型中,初始学习曲线约在病例序号201例终止。
  • 初始学习曲线后,病例量与结局关系不再明显。
  • 仅Sapien 3分析中,未证明存在学习曲线或病例量与结局关系。
  • Sapien 3在球囊扩张瓣膜初治中心分析中,同样未证明存在学习曲线或病例量与结局关系。

临床怎么用

  • 当前代球囊扩张式TAVR中心即使早期病例经验也应预期获得一致优异结局。
  • 全体球囊扩张式TAVR病例经验约200例后,病例量与结局关系不再明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given conflicting findings of previous studies, much remains to be understood regarding a volume-outcomes relationship (VOR) in transcatheter aortic valve replacement (TAVR). OBJECTIVES: The purpose of this study was: 1) to determine if, after the initial learning curve (LC), a VOR for balloon-expandable (BE) TAVR persisted; and 2) to determine if LCs and VORs differed across different device generations. METHODS: Data collected by the TVT registry for BE valve implants from November 2011 through January 2017 were included in this analysis (n = 61,949). Primary outcomes included 30-day all-cause mortality, stroke, and major vascular complications. For each center, all implants were ordered chronologically according to case sequence number (CS#). To determine where the learning curve terminated (LCT), a grid search analysis was applied across a range of CS# from 10 to 300 by increments of 1. After LCT, the VOR was assessed by examining case volume/month by center. This analysis was performed separately for: 1) all BE valve types; 2) Sapien 3 (S3) only; and 3) S3 in BE valve naïve sites. RESULTS: In experience with all commercially available BE valve types, there was an initial LC that terminates around case #201. After the initial LC, a volume-outcomes relationship was no longer evident. In analysis limited to S3, there was no demonstrable LC or VOR. Likewise, there was no demonstrable LC or VOR with S3 for BE valve naïve sites. CONCLUSIONS: After a case experience of 200 cases, there was LCT; subsequent to initial learning, a VOR was no longer evident. In the S3-only analysis, there was no LC or no demonstrable VOR. With current-generation BE-TAVR, centers should expect to achieve consistently excellent outcomes even during early case experience.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Russo MJ, McCabe JM, Thourani VH, et al. Case Volume and Outcomes After TAVR With Balloon-Expandable Prostheses: Insights From TVT Registry. J Am Coll Cardiol. 2019. PMID: 30704575. doi:10.1016/j.jacc.2018.11.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。